Eli Lilly became the first drugmaker to hit a $1 trillion market valuation after blockbuster performance from its obesity portfolio transformed the company’s revenue outlook. The milestone reflects outsized demand for GLP‑1 and related therapies and reassures investors about Lilly’s commercial reach beyond traditional diabetes markets. The valuation jump highlights how weight‑loss medicines reshaped competitive dynamics across pharma, prompting strategic responses from rivals, payers and employers. Market watchers will track sustainability of demand, reimbursement dynamics and regulatory scrutiny around long‑term use.